学術情報 -AJRCCM(ブルージャーナル)-

本誌は、American Thoracic Society(米国胸部学会)の発行するAmerican Journal of Respiratory and Critical Care Medicineをもとに、シュプリンガー・ジャパン株式会社が公正中立の立場で論文選択、翻訳等を含む作業全般を担っている医療関係者向けの資材です。

弊社は、医療関係者に有益な情報を提供することを通じて医療に貢献することを目的に本資材の提供を行っており、本資材作成にかかる費用を負担しています。

本資材には本邦における未承認の医薬品、効能・効果及び用法・用量等の情報が含まれる場合がありますが、これを推奨するものではありません。

本資材を受領される際には、以下の内容をご確認いただきたく存じます。

  • 本資材に記載された薬剤の使用にあたっては、最新の添付文書をご参照ください。
  • 本資材は医療関係者からの求めに応じて提供するものであり、企業が積極的に提供するものではありません。

2018年09月 -PART 02-

肺結核に対する高用量リファンピシンの有効性及び安全性:無作為化比較試験

Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis A Randomized Controlled Trial Am J Respir Crit Care Med 2018; 198(5): 657-666

黄色ブドウ球菌は上皮細胞由来サイトカインを介して粘膜に2型免疫応答を誘導する

Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell-derived Cytokines Am J Respir Crit Care Med 2018; 198(4): 452-463

慢性閉塞性肺疾患(COPD)の一般診療集団におけるCOPD増悪の自然経過

Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice‒based Population with Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med 2018; 198(4): 464-471

2018年09月 -PART 01-

健康マウスの肺微生物叢は変動が大きく、環境に応じてクラスターを形成し、ベースライン肺自然免疫の変動を反映する

The Lung Microbiota of Healthy Mice Are Highly Variable, Cluster by Environment, and Reflect Variation in Baseline Lung Innate Immunity Am J Respir Crit Care Med 2018; 198(4): 497-508

夜間の受動的な生理的モニタリングは小児喘息増悪の早期発見を可能にする概念実証研究

Passive Nocturnal Physiologic Monitoring Enables Early Detection of Exacerbations in Children with Asthma Am J Respir Crit Care Med 2018; 198(3): 320-328

慢性閉塞性肺疾患患者における長期3剤併用療法からインダカテロール/グリコピロニウムへの治療減量[SUNSET(Study to Understand the Safety and Efficacy of ICS Withdrawal from Triple Therapy in COPD) 研究]:無作為化二重盲検トリプルダミー臨床試験

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial Am J Respir Crit Care Med 2018; 198(3): 329-339

Selected articles from AJRCCM. Copyright 2018 by the American Thoracic Society. All rights reserved. The ideas and opinions expressed in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) or other associated publications do not necessarily reflect those of the American Thoracic Society (ATS). The authors, editors or ATS are not responsible for errors or omissions of articles published in print or online from AJRCCM or other associated ATS publications. Although great care has been taken in compiling the content of this publication, neither ATS or their servants are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising there from. Approved product information should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ATS assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. 

The translation is © 2018 American Thoracic Society. American Thoracic Society or Springer Healthcare takes no responsibility for the accuracy of the translation from the published English original and are not liable for any errors that may occur.